What matters to patients and doctors when choosing first lung cancer treatment
Surveys patients and physicians about choosing EGFR-TKI medicines for advanced non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
Key facts
- Where
- Chengdu, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage IV non-small cell lung cancer who are taking or took an EGFR-TKI as first treatment. It also asks certain senior doctors to fill in a survey about treatment preferences.
- Age
- 18 years or older (patients).
- Sex
- All sexes can join.
- Disease stage
- Stage IV non-small cell lung cancer (NSCLC).
- Earlier treatment
- Patients are taking, or have taken, a first-line EGFR-TKI treatment.
Main reasons for not taking part
- Patients with a communication barrier cannot join.
- Patients with signs of cognitive impairment that would prevent taking part cannot join.
- Doctors who manage fewer than 3 stage IV NSCLC patients with first-line EGFR-TKI per month cannot join.
Read by machine on 12 November 2026.
Where in China
- ChengduHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07413757
- Record updated
- 9 October 2026
- Original description
This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.Read full original descriptionShow less
A Cross-sectional Survey-based Study Using Preference Elicitation Method to Assess Decision-making Impact Factor of Chinese Patients and Physicians for First-line EGFR-TKIs Treatment of Stage IV NSCLC (CHOICE)
This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.
Inclusion: The following inclusion criteria must be met in order to be enrolled in the stage 1:; Patient:; Provide informed consent; 18 years or older; Diagnosed with stage IV NSCLC; Currently receiving or previously received 1L EGFR-TKI treatment; Without communication barrier; Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter; Physician:; Provide informed consent; Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals; Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month; Holding the title of associate chief physician or higher; The following inclusion criteria must be met in order to be enrolled in the stage 2:; Patient:; Provide informed consent; 18 years or older; Diagnosed with stage IV NSCLC; Currently receiving or previously received 1L EGFR-TKI treatment; Without communication barrier; Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter; Physician:; Provide informed consent; Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals; Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month; Holding the title of attending physician or higher.
Exclusion: Not applicable.